stockportfolio.pro
Roivant Sciences Ltd. (ROIV)
Healthcare · Biotechnology · NasdaqGS
Roivant Sciences Ltd. revenue & earnings — last 6 fiscal years
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenue | $23.80M | $55.29M | $61.28M | $124.80M | $29.05M | $8.26M |
| Gross profit | — | — | — | — | — | — |
| Net income | $-809.23M | $-845.26M | $-1.01B | $4.35B | $-171.98M | $-299.77M |
| Net margin | -3400.9% | -1528.9% | -1646.6% | 3484.9% | -592.0% | -3629.2% |
Source: Roivant Sciences Ltd. SEC filings (10-K).
Explore 6 years of Roivant Sciences Ltd. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ROIV in your portfolio →
About Roivant Sciences Ltd.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
Roivant Sciences Ltd. — frequently asked questions
What is Roivant Sciences Ltd.'s revenue?
Roivant Sciences Ltd. (ROIV) reported revenue of $8.26M for fiscal year 2026, down 71.6% from the prior year, according to its SEC filings.
Is Roivant Sciences Ltd. profitable?
No — ROIV reported a net loss of $-299.77M in fiscal 2026.
What is ROIV's P/E ratio?
Roivant Sciences Ltd. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Roivant Sciences Ltd. growing?
ROIV's revenue grew at roughly -19.1% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Roivant Sciences Ltd.'s official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.